113 related articles for article (PubMed ID: 24294959)
1. Disruption of pocket protein dream complexes by E7 proteins of different types of human papillomaviruses.
Nor Rashid N; Yusof R; Watson RJ
Acta Virol; 2013; 57(4):447-51. PubMed ID: 24294959
[TBL] [Abstract][Full Text] [Related]
2. HPV 16E7 and 48E7 proteins use different mechanisms to target p130 to overcome cell cycle block.
Nor Rashid N; Yong ZL; Yusof R; Watson RJ
Virol J; 2016 Jan; 13():2. PubMed ID: 26728921
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal degradation of p130 facilitate cell cycle deregulation and impairment of cellular differentiation in high-risk Human Papillomavirus 16 and 18 E7 transfected cells.
Gandhi S; Nor Rashid N; Mohamad Razif MF; Othman S
Mol Biol Rep; 2021 Jun; 48(6):5121-5133. PubMed ID: 34169395
[TBL] [Abstract][Full Text] [Related]
4. The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.
Wang J; Zhou D; Prabhu A; Schlegel R; Yuan H
PLoS Pathog; 2010 Sep; 6(9):e1001089. PubMed ID: 20824099
[TBL] [Abstract][Full Text] [Related]
5. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development.
Mansour M; Touka M; Hasan U; Bellopede A; Smet A; Accardi R; Gabet AS; Sylla BS; Tommasino M
Virology; 2007 Oct; 367(1):1-9. PubMed ID: 17568647
[TBL] [Abstract][Full Text] [Related]
6. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation.
Zhang B; Chen W; Roman A
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):437-42. PubMed ID: 16381817
[TBL] [Abstract][Full Text] [Related]
7. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.
Gonzalez SL; Stremlau M; He X; Basile JR; Münger K
J Virol; 2001 Aug; 75(16):7583-91. PubMed ID: 11462030
[TBL] [Abstract][Full Text] [Related]
8. A B-myb--DREAM complex is not critical to regulate the G2/M genes in HPV-transformed cell lines.
Rashid NN; Yusof R; Watson RJ
Anticancer Res; 2014 Nov; 34(11):6557-63. PubMed ID: 25368258
[TBL] [Abstract][Full Text] [Related]
9. A naturally occurring variant of HPV-16 E7 exerts increased transforming activity through acquisition of an additional phospho-acceptor site.
Zine El Abidine A; Tomaić V; Bel Haj Rhouma R; Massimi P; Guizani I; Boubaker S; Ennaifer E; Banks L
Virology; 2017 Jan; 500():218-225. PubMed ID: 27829177
[TBL] [Abstract][Full Text] [Related]
10. HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner.
Rabachini T; Boccardo E; Andrade R; Perez KR; Nonogaki S; Cuccovia IM; Villa LL
BMC Cancer; 2018 Apr; 18(1):485. PubMed ID: 29703186
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures.
Westphal K; Akgül B; Storey A; Nindl I
Cell Oncol; 2009; 31(3):213-26. PubMed ID: 19478389
[TBL] [Abstract][Full Text] [Related]
12. Low- and high-risk human papillomavirus E7 proteins regulate p130 differently.
Barrow-Laing L; Chen W; Roman A
Virology; 2010 May; 400(2):233-9. PubMed ID: 20189212
[TBL] [Abstract][Full Text] [Related]
13. Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway.
Fischer M; Uxa S; Stanko C; Magin TM; Engeland K
Sci Rep; 2017 Jun; 7(1):2603. PubMed ID: 28572607
[TBL] [Abstract][Full Text] [Related]
14. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb.
Jansma AL; Martinez-Yamout MA; Liao R; Sun P; Dyson HJ; Wright PE
J Mol Biol; 2014 Dec; 426(24):4030-4048. PubMed ID: 25451029
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression.
Morandell D; Rostek U; Bouvard V; Campo-Fernández B; Fiedler M; Jansen-Dürr P; Zwerschke W
Virology; 2008 Sep; 379(1):20-9. PubMed ID: 18649911
[TBL] [Abstract][Full Text] [Related]
16. A humanized mouse model of HPV-associated pathology driven by E7 expression.
Buitrago-Pérez Á; Hachimi M; Dueñas M; Lloveras B; Santos A; Holguín A; Duarte B; Santiago JL; Akgül B; Rodríguez-Peralto JL; Storey A; Ribas C; Larcher F; del Rio M; Paramio JM; García-Escudero R
PLoS One; 2012; 7(7):e41743. PubMed ID: 22911850
[TBL] [Abstract][Full Text] [Related]
17. Restoring the DREAM Complex Inhibits the Proliferation of High-Risk HPV Positive Human Cells.
James CD; Saini S; Sesay F; Ko K; Felthousen-Rusbasan J; Iness AN; Nulton T; Windle B; Dozmorov MG; Morgan IM; Litovchick L
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33513914
[TBL] [Abstract][Full Text] [Related]
18. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes.
Genovese NJ; Banerjee NS; Broker TR; Chow LT
J Virol; 2008 May; 82(10):4862-73. PubMed ID: 18321970
[TBL] [Abstract][Full Text] [Related]
19. YAP1 activation by human papillomavirus E7 promotes basal cell identity in squamous epithelia.
Hatterschide J; Castagnino P; Kim HW; Sperry SM; Montone KT; Basu D; White EA
Elife; 2022 Feb; 11():. PubMed ID: 35170430
[TBL] [Abstract][Full Text] [Related]
20. A Reverse Structure-based Design of HPV E7 Inhibitor.
Tan WC; Othman S; Lim SK; Rashid NN; Heh CH
Curr Comput Aided Drug Des; 2022; 18(4):318-325. PubMed ID: 35538818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
